Study about glucose and lipid metabolism of DPP-4 inhibitor versus ipragliflozin in inadequately controlled type 2 diabetes
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 May 2017
At a glance
- Drugs Ipragliflozin (Primary) ; CD26 antigen inhibitors
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LEVELUP trial
- 11 May 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Apr 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.
- 17 Oct 2014 New trial record